This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Best-Performing Leveraged ETFs of Last Week
by Sanghamitra Saha
USAR-linked leveraged ETFs soared last week as rare-earth stocks jumped, while natural gas and gold plays surged amid tariffs and winter shocks.
LHC Group (LHCG) Forays Into Oregon With New Acquisition
by Zacks Equity Research
LHC Group (LHCG) acquires Home 'n Hospice to expand its existing footprint in Idaho.
PerkinElmer (PKI) Boosts Cell Biology Portfolio With Buyout
by Zacks Equity Research
PerkinElmer (PKI) enters into an agreement to acquire Nexcelom that will enable the former to boost its efforts when it comes to solutions for drug discovery.
Luminex (LMNX) to Get Acquired by DiaSorin for Around $1.8B
by Zacks Equity Research
Luminex (LMNX) to be acquired by DiaSorin for around $1.8 billion. This is likely to advance its technology and solutions' foothold outside the United States.
Strength Seen in Luminex (LMNX): Can Its 12.4% Jump Turn into More Strength?
by Zacks Equity Research
Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Luminex (LMNX) Files EUA Application for New Respiratory Assay
by Zacks Equity Research
Luminex (LMNX) develops the combined assay to rapidly deliver clear solutions about respiratory infections from a single test.
Luminex (LMNX) Up 14.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex (LMNX) Surges 6.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.